<DOC>
	<DOCNO>NCT02877355</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial , investigate effect upper gastrointestinal disease pharmacokinetics ( exposure trial drug body ) oral semaglutide subject type 2 diabetes .</brief_summary>
	<brief_title>Investigation Effect Upper Gastrointestinal Disease Pharmacokinetics Oral Semaglutide Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<criteria>Male female , age 1880 year ( inclusive ) time sign informed consent Body mass index ( BMI ) 18.539.9 kg/m^2 ( inclusive ) Subjects diagnose clinically type 2 diabetes mellitus least 180 day prior first screen visit For subject upper gastrointestinal ( GI ) disease : Diagnosed chronic gastritis and/or gastroesophageal reflux disease ( GERD ) screen Female pregnant , breastfeed intend become pregnant childbearing potential use highly effective contraceptive method ( adequate contraceptive measure require local regulation practice ) . ( Highly effective contraceptive method consider failure rate le 1 % undesired pregnancy per year include surgical sterilisation , hormonal intrauterine device ( coil ) , oral hormonal contraceptive , sexual abstinence surgically sterilise partner ) History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Unable unwilling refrain smoking inpatient period Any blood draw excess 50 mL past 30 day , donation blood plasma excess 400 mL within 90 day first screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>